Key regions: United Kingdom, Brazil, Europe, France, Canada
Belgium, a country in Western Europe, has been experiencing a significant rise in the Anti-Fibrinolytic Drugs market.
Customer preferences: The Anti-Fibrinolytic Drugs market in Belgium is primarily driven by the rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease. Additionally, the increasing number of surgeries being performed in the country has also contributed to the growth of this market. Patients undergoing surgeries require Anti-Fibrinolytic Drugs to prevent excessive bleeding during and after the procedure.
Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Belgium is the shift towards personalized medicine. With advancements in technology and research, healthcare providers are now able to tailor treatment plans based on an individual's genetic makeup, which has resulted in more effective and efficient treatment outcomes. Moreover, the market is witnessing an increase in the number of product launches by key players, which is further driving market growth.
Local special circumstances: Belgium has a well-established healthcare system that provides universal coverage to its citizens. This has resulted in higher accessibility to healthcare services, including medicines. Additionally, the country has a high prevalence of bleeding disorders, which has led to an increased demand for Anti-Fibrinolytic Drugs. Furthermore, the presence of key players in the country has also contributed to the growth of the market.
Underlying macroeconomic factors: The Belgian economy has been growing steadily over the past few years, which has resulted in an increase in healthcare spending. This has provided a boost to the Anti-Fibrinolytic Drugs market, as healthcare providers are now able to invest more in research and development, as well as the procurement of medicines. Additionally, the aging population in the country has also contributed to the growth of the market, as older individuals are more prone to bleeding disorders and require Anti-Fibrinolytic Drugs for treatment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
